PPARs: Modulating Lipotoxicity and Thus Inhibiting Fibrosis

Overview

Journal Hormones (Athens)

Specialty Endocrinology

Date 2024 Nov 5

PMID 39500811

Authors

Wen-Rui Li

Chunping Zhang

Jing Wang

Affiliations

Soon will be listed here.

Abstract

Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear hormone receptor family of ligand-activated receptors and are known for their roles as key factors in the regulation of lipid metabolism. In the more than three decades since their discovery, most reports on PPARs have focused on their roles in lipid metabolism, and a portion of the new research has also focused on the relationship between PPARs and fibrosis. Interestingly, lipid metabolism disorders and fibrosis are also inextricably linked. This implies that PPARs, lipid metabolism and fibrosis are interrelated. On this basis, we have summarized the molecular mechanisms of PPARs regulating fibrosis through lipid metabolism and PPARγ directly regulating fibrosis, and pointed out the contradictions and enigmas that need to be further explored in the processes of PPARs regulating lipid metabolism and fibrosis. The aim of the present review is to provide new ideas for PPARs for the treatment of lipid metabolism disorders and fibrosis.

References

Issemann I, Green S . Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990; 347(6294):645-50. DOI: 10.1038/347645a0. View

Tontonoz P, Spiegelman B . Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem. 2008; 77:289-312. DOI: 10.1146/annurev.biochem.77.061307.091829. View

Hummasti S, Tontonoz P . The peroxisome proliferator-activated receptor N-terminal domain controls isotype-selective gene expression and adipogenesis. Mol Endocrinol. 2006; 20(6):1261-75. DOI: 10.1210/me.2006-0025. View

Lamas Bervejillo M, Ferreira A . Understanding Peroxisome Proliferator-Activated Receptors: From the Structure to the Regulatory Actions on Metabolism. Adv Exp Med Biol. 2019; 1127:39-57. DOI: 10.1007/978-3-030-11488-6_3. View

Li Z, Luo L, Yu W, Li P, Ou D, Liu J . PPARγ phase separates with RXRα at PPREs to regulate target gene expression. Cell Discov. 2022; 8(1):37. PMC: 9043196. DOI: 10.1038/s41421-022-00388-0. View

Kang Z, Fan R . PPARα and NCOR/SMRT corepressor network in liver metabolic regulation. FASEB J. 2020; 34(7):8796-8809. DOI: 10.1096/fj.202000055RR. View

Mirza A, Althagafi I, Shamshad H . Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications. Eur J Med Chem. 2019; 166:502-513. DOI: 10.1016/j.ejmech.2019.01.067. View

Hamblin M, Chang L, Fan Y, Zhang J, Chen Y . PPARs and the cardiovascular system. Antioxid Redox Signal. 2008; 11(6):1415-52. PMC: 2737093. DOI: 10.1089/ars.2008.2280. View

Janssen A, Betzel B, Stoopen G, Berends F, Janssen I, Peijnenburg A . The impact of PPARα activation on whole genome gene expression in human precision cut liver slices. BMC Genomics. 2015; 16:760. PMC: 4599789. DOI: 10.1186/s12864-015-1969-3. View

10.

Imai T, Takakuwa R, Marchand S, Dentz E, Bornert J, Messaddeq N . Peroxisome proliferator-activated receptor gamma is required in mature white and brown adipocytes for their survival in the mouse. Proc Natl Acad Sci U S A. 2004; 101(13):4543-7. PMC: 384783. DOI: 10.1073/pnas.0400356101. View

11.

Semple R, Chatterjee V, ORahilly S . PPAR gamma and human metabolic disease. J Clin Invest. 2006; 116(3):581-9. PMC: 1386124. DOI: 10.1172/JCI28003. View

12.

Ahmadian M, Suh J, Hah N, Liddle C, Atkins A, Downes M . PPARγ signaling and metabolism: the good, the bad and the future. Nat Med. 2013; 19(5):557-66. PMC: 3870016. DOI: 10.1038/nm.3159. View

13.

Wang Y, Lee C, Tiep S, Yu R, Ham J, Kang H . Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell. 2003; 113(2):159-70. DOI: 10.1016/s0092-8674(03)00269-1. View

14.

Roberts L, Murray A, Menassa D, Ashmore T, Nicholls A, Griffin J . The contrasting roles of PPARδ and PPARγ in regulating the metabolic switch between oxidation and storage of fats in white adipose tissue. Genome Biol. 2011; 12(8):R75. PMC: 3245615. DOI: 10.1186/gb-2011-12-8-r75. View

15.

Zhou Y, Lin S, Zhang L, Li Y . Resveratrol prevents renal lipotoxicity in high-fat diet-treated mouse model through regulating PPAR-α pathway. Mol Cell Biochem. 2015; 411(1-2):143-50. DOI: 10.1007/s11010-015-2576-y. View

16.

Jao T, Nangaku M, Wu C, Sugahara M, Saito H, Maekawa H . ATF6α downregulation of PPARα promotes lipotoxicity-induced tubulointerstitial fibrosis. Kidney Int. 2019; 95(3):577-589. DOI: 10.1016/j.kint.2018.09.023. View

17.

Dai L, Bhargava P, Stanya K, Alexander R, Liou Y, Jacobi D . Macrophage alternative activation confers protection against lipotoxicity-induced cell death. Mol Metab. 2017; 6(10):1186-1197. PMC: 5641682. DOI: 10.1016/j.molmet.2017.08.001. View

18.

Medina-Gomez G, Gray S, Yetukuri L, Shimomura K, Virtue S, Campbell M . PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet. 2007; 3(4):e64. PMC: 1857730. DOI: 10.1371/journal.pgen.0030064. View

19.

Ravnskjaer K, Frigerio F, Boergesen M, Nielsen T, Maechler P, Mandrup S . PPARdelta is a fatty acid sensor that enhances mitochondrial oxidation in insulin-secreting cells and protects against fatty acid-induced dysfunction. J Lipid Res. 2009; 51(6):1370-9. PMC: 3035500. DOI: 10.1194/jlr.M001123. View

20.

Wynn T, Ramalingam T . Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012; 18(7):1028-40. PMC: 3405917. DOI: 10.1038/nm.2807. View